TY - JOUR
T1 - Racial and Ethnic Disparities in Outcomes After Breast-Conserving Therapy and Endocrine Therapy for DCIS
T2 - A Post-Hoc Analysis of the NSABP B-35 Randomized Clinical Trial
AU - Kantor, Olga
AU - King, Tari A.
AU - Jones, Alyssa
AU - Glass, Charity
AU - Leonard, Saskia J.
AU - Ogayo, Esther R.
AU - Mayer, Erica L.
AU - Chavez-MacGregor, Mariana
AU - Newman, Lisa A.
AU - Freedman, Rachel A.
AU - Mittendorf, Elizabeth A.
N1 - Publisher Copyright:
© 2023, Society of Surgical Oncology.
PY - 2023/12
Y1 - 2023/12
N2 - Background: Racial and ethnic disparities in outcomes after treatment for ductal carcinoma in situ (DCIS) are largely unknown. The objective of this study was to examine breast cancer outcomes by race and ethnicity in the National Surgical Adjuvant Breast and Bowel Project (NSABP) B-35 clinical trial. Patients and Methods: The NSABP B-35 trial randomized postmenopausal women with hormone receptor-positive DCIS treated with breast-conserving therapy to 5 years of tamoxifen or anastrozole. In total, 3104 women were enrolled between 2003 and 2006. For this analysis, patients without complete self-reported race and ethnicity or with immediate trial dropout were excluded. Kaplan–Meier curves and adjusted Cox-proportional hazards models were used for analyses. Results: Of the 3061 women included, 2614 (85.4%) were non-Hispanic white (NHW), 255 (8.3%) were non-Hispanic Black (NHB), 95 (3.1%) were Hispanic, and 96 (3.1%) were Asian or Pacific Islander (API). Endocrine therapy assignment and duration were well balanced between racial and ethnic groups. Median follow-up was 9 years; unadjusted Kaplan–Meier curves did not show any racial differences in disease events. Adjusted Cox-proportional hazards models found API (versus NHW) race to be associated with higher local recurrence [hazard ratio (HzR) 2.45, p = 0.035] and NHB race to be associated with higher distant recurrence (HzR 5.03, p = 0.020) and breast cancer mortality (HzR 3.83, p = 0.046). Conclusions: Despite similar locoregional treatments and standard endocrine therapy in a clinical trial population, racial and ethnic disparities exist in long-term outcomes for hormone-receptor-positive DCIS. These findings suggest that factors outside of access and treatment may impact DCIS outcomes by race and ethnicity.
AB - Background: Racial and ethnic disparities in outcomes after treatment for ductal carcinoma in situ (DCIS) are largely unknown. The objective of this study was to examine breast cancer outcomes by race and ethnicity in the National Surgical Adjuvant Breast and Bowel Project (NSABP) B-35 clinical trial. Patients and Methods: The NSABP B-35 trial randomized postmenopausal women with hormone receptor-positive DCIS treated with breast-conserving therapy to 5 years of tamoxifen or anastrozole. In total, 3104 women were enrolled between 2003 and 2006. For this analysis, patients without complete self-reported race and ethnicity or with immediate trial dropout were excluded. Kaplan–Meier curves and adjusted Cox-proportional hazards models were used for analyses. Results: Of the 3061 women included, 2614 (85.4%) were non-Hispanic white (NHW), 255 (8.3%) were non-Hispanic Black (NHB), 95 (3.1%) were Hispanic, and 96 (3.1%) were Asian or Pacific Islander (API). Endocrine therapy assignment and duration were well balanced between racial and ethnic groups. Median follow-up was 9 years; unadjusted Kaplan–Meier curves did not show any racial differences in disease events. Adjusted Cox-proportional hazards models found API (versus NHW) race to be associated with higher local recurrence [hazard ratio (HzR) 2.45, p = 0.035] and NHB race to be associated with higher distant recurrence (HzR 5.03, p = 0.020) and breast cancer mortality (HzR 3.83, p = 0.046). Conclusions: Despite similar locoregional treatments and standard endocrine therapy in a clinical trial population, racial and ethnic disparities exist in long-term outcomes for hormone-receptor-positive DCIS. These findings suggest that factors outside of access and treatment may impact DCIS outcomes by race and ethnicity.
UR - http://www.scopus.com/inward/record.url?scp=85173044861&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85173044861&partnerID=8YFLogxK
U2 - 10.1245/s10434-023-14344-z
DO - 10.1245/s10434-023-14344-z
M3 - Article
C2 - 37777685
AN - SCOPUS:85173044861
SN - 1068-9265
VL - 30
SP - 8404
EP - 8411
JO - Annals of surgical oncology
JF - Annals of surgical oncology
IS - 13
ER -